Table of contents

Original Articles

• Neoadjuvant chemotherapy for advanced ovarian cancer (1 September, 1996)

  E. Surwit, J. Childers, I. Atlas, M. Nour, K. Hatch, A. Hallum, D. Alberts
• Risk of second malignant neoplasms following female genital tract cancers in New South Wales (Australia), 1972-91 (1 September, 1996)

  M. R.E. McCredie, G. J. Macfarlane, M. S. Coates, R. A. Osborn
• Small cell carcinoma of the uterine cervix: overexpression of p53, BCL-2 and CD-44 (1 September, 1996)

  C. Faul, S. Kounelis, K. Karasek, H. Papadaki, J. Greenberger, M. W. Jones
• Vimentin intermediate filament expression in uterine cervical carcinoma (1 September, 1996)

  C.R. Hunt, R. J. Hale, C.H. Buckley
• For stage III epithelial ovarian cancer the initial level of expression of CA125 does not correlate with survival in women who respond to treatment (1 September, 1996)

  J.A. Latimer, C. G. Beng, M. L.J. Davy
• Angiogenesis in endometrial carcinoma (1 September, 1996)

  K. G. Morgan, N. Wilkinson, C. H. Buckley
• A PCR study on the coexistence of herpes simplex virus, cytomegalovirus and human papillomavirus DNAs in cervical neoplasia (1 September, 1996)

  J.-J. Baldauf, M. Dreyfus, J. Ritter, P. Meyer, E. Philippe, G. Obert
• Patterns of recurrence following hysterectomy and radiation for cervical carcinoma: relationship to residual disease and brachytherapy techniques (1 September, 1996)

  J. Lattanzi, B. Erickson
• Lymph node involvement in primary carcinoma of the fallopian tube (1 September, 1996)

  G. Cormio, A. Lissoni, A. Maneo, M. Marzola, A. Gabriele, C. Mangioni
• Combined high-dose platinum and etoposide in previously untreated ovarian cancer patients with residual disease (1 September, 1996)

  G. Strauss, B. Lund, M. Hansen, O. P. Hansen, H.H. Hansen
• Neurotoxicity of cisplatin +/- reduced glutathione in the first-line treatment of advanced ovarian cancer (1 September, 1996)

  G. Bogliun, L. Marzorati, M. Marzola, M. D. Miceli, M. G. Cantù, G. Cavaletti